BioCentury
ARTICLE | Clinical News

Apatorsen: Phase II data

January 25, 2016 8:00 AM UTC

The double-blind, U.S. Phase II Spruce trial in about 155 patients with previously untreated metastatic non-squamous NSCLC showed that once-weekly 600 mg IV apatorsen plus carboplatin and Alimta peme...